HAI Serological Testing Services

The contract entails the performance of hemagglutination inhibition assays on human serum samples to evaluate the effectiveness of influenza vaccines and support public health responses during influenza outbreaks. Services include the end-to-end processing of biological samples, conduct of laboratory assays under established protocols, rigorous data analysis to determine antibody titers, and timely reporting of results to meet public health objectives. All work must adhere to high standards of accuracy and consistency to ensure reliable serological data that informs vaccine strategy and outbreak containment efforts. The contract is a subcontract issued under the CDC Office of Acquisition Services within the Department of Health and Human Services, with the North American Industry Classification System code 541611 for medical and diagnostic laboratories. Performance is expected to occur in Atlanta, Georgia, aligning with the CDC’s operational hub. The solicitation was posted on May 18, 2026, and while no specific set-aside or point of contact details are provided, the work is critical to national influenza surveillance and vaccine efficacy monitoring programs.